PP
Partho P. Sengupta, MD
Rutgers Robert Wood Johnson · SAB Chair
About HeartSciences
Healthcare information technology for the heart.
HeartSciences is a healthcare technology company focused on modernizing ECG workflow through connected software, interoperable reporting, AI-enabled clinical infrastructure, and a next-generation ECG acquisition device.
A better ECG workflow for modern cardiology.
HeartSciences helps health systems bring ECG review, reporting, and AI-ECG into one connected workflow that fits the way clinicians already work.
2014
Founded in Southlake, TX
Nasdaq
HSCS · HSCSW
ISO 13485
Certified
Scientific advisory board
Cardiologists and AI researchers shaping the work.
JN
Jagat Narula, MD, PhD
Mount Sinai Heart
GN
Girish Nadkarni, MD, MPH
Mount Sinai
AV
Akhil Vaid, MBBS
Mount Sinai · Data Science
JL
Joshua Lampert, MD
Mount Sinai · Cardiology
BG
Ben Glicksberg, PhD
Mount Sinai · AI Research
JS
Jordan Strom, MD, MSc
Beth Israel Deaconess
Company
The journey so far.
- 2014
HeartSciences founded
Incorporated in Southlake, Texas with a vision of applying AI to the standard ECG.
- 2017
wavECG developed
First-generation MyoVista wavECG device built on continuous wavelet transform signal processing.
- 2019
First clinical studies
Initiated multi-site research partnerships with academic medical centers.
- 2021
Nasdaq listing
Listed on Nasdaq (HSCS / HSCSW), capitalizing the platform build-out.
- 2022
Mount Sinai license agreements
Licensed AI cardiovascular algorithm IP from the Icahn School of Medicine at Mount Sinai.
- 2024
FDA Breakthrough Designation
AI-ECG algorithm for aortic stenosis received FDA Breakthrough Device Designation.
- 2025
MyoVista Insights v1.1
Major usability upgrade shipped; FDA 510(k) submission filed for the wavECG device.
- 2026
Cibolo Health partnership
MyoVista Insights endorsed across a 123-hospital independent network in six states.
Join us
Partner with HeartSciences.
Whether you're a clinician, health system, or researcher: we'd like to hear from you.